Predict Parkinson in essential tremor
- Trial ID
- NCT07428447
- Official Title
- Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
- Goal
- Predict Parkinson in essential tremor
- Status
- RECRUITING
- Sponsor
- CND Life Sciences
- Study Type
- OBSERVATIONAL
- Enrollment
- 300 participants
- Conditions
- Essential Tremor, Movement Disorders, Essential Tremor, Essential Tremor-plus
Plain-Language Summary
The goal is to see whether phosphorylated alpha-synuclein, a Parkinson's-related protein, shows up in the skin of people with essential tremor or ET-plus and can predict who is more likely to go on to develop Parkinson's disease. The approach is a biomarker test using small skin biopsies to look for phosphorylated alpha-synuclein, which reflects the abnormal protein clumps seen in Parkinson's; this is not a treatment and it does not affect or interact with levodopa. The study is looking for adults 50 to 85 years old with ET or ET-plus by the 2018 MDS criteria who can consent and complete procedures, and it excludes people with other neurodegenerative disorders, abnormal DaTscan, active bleeding or wound-healing risks, current use of carbidopa-levodopa, or anticoagulant/dual antiplatelet therapy.
Locations
- CND Clinical Research Center, Scottsdale, Arizona, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to see whether phosphorylated alpha-synuclein, a Parkinson's-related protein, shows up in the skin of people with essential tremor or ET-plus and can predict who is more likely to go on to develop Parkinson's disease. The approach is a biomarker test using small skin biopsies to look for phosphorylated alpha-synuclein, which reflects the abnormal protein clumps seen in Parkinson's; this is not a treatment and it does not affect or interact with levodopa. The study is looking for adults 50 to 85 years old with ET or ET-plus by the 2018 MDS criteria who can consent and complete procedures, and it excludes people with other neurodegenerative disorders, abnormal DaTscan, active bleeding or wound-healing risks, current use of carbidopa-levodopa, or anticoagulant/dual antiplatelet therapy.
- Who can participate?
- Participants must be between 50 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 11 months.